WRN Helicase: Synthetic Lethal Drug Discovery Landscape & Assay Solutions

By admin
20 Aug 2026
Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for MSI-H Cancer Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for WRN helicase drug discovery. Select your modality below:

Component / Network	Product Description	Product Link
Antigen	WRN Helicase Domain / Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Catalytic-dead mutant (E84A, D82A) available as negative controls.	View WRN Products
Gene Delivery	WRN Promise-ORF / Lentivirus Full-length ORF for stable cell lines in MSI-H models (HCT116, LoVo).	View WRN Products
Benchmark Ab	Anti-WRN (Research Grade) Recombinant positive control for Western and IP.	View WRN Products
Validator	WRN siRNA Set For synthetic lethal validation and specificity checks.	View WRN Products
Selectivity Counter-screen	BLM Helicase (RecQ2) Close paralog for off-target liability assessment.	View BLM Products
Selectivity Counter-screen	RECQL5 Helicase RecQ family member for broad selectivity profiling.	View RECQL5 Products
Synthetic Lethal Partner	MLH1 Mutant Protein MMR pathway component; predictive biomarker for WRN sensitivity.	View MLH1 Products
Related DDR Target	PARP1 Synergistic DNA damage response pathway target; common combination partner.	View PARP1 Products
Related DDR Target	POLQ Alternative synthetic lethality target in DNA repair-deficient tumors.	View POLQ Products

Critical Assay Challenge	The TarMart Advantage (Technical Spec)
RecQ Family Selectivity (Avoid BLM/RECQL1 toxicity)	Highly purified WRN, BLM, and RECQL5 Helicase Domains (>95% purity, Sequence Verified by Mass Spec) for orthogonal counter-screening
Helicase Activity Quantification	ATP-binding domain proteins with Theoretical MW confirmed; suitable for FRET-based DNA unwinding and ATPase assays
Synthetic Lethal Validation	Validated siRNA and Lentivirus particles for isogenic MSI-H vs MSS cell line construction
Catalytic Mechanism Differentiation	Helicase-dead (E84A) and Exonuclease-dead (D82A) mutants available as rigorous negative controls

Live WRN R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The WRN synthetic lethal paradigm represents one of the most promising precision oncology targets for microsatellite instability-high (MSI-H) malignancies. Following the validation of WRN dependency in MSI-H colorectal, gastric, and endometrial cancers, the competitive landscape has rapidly evolved from academic proof-of-concept to robust clinical development. First-generation small molecule inhibitors have entered Phase I/II trials, establishing the helicase domain as the primary druggable pocket.

Key players include Ideaya Biosciences (lead candidate IDEAYA-WRN, Phase I/II, partnered with Genentech for PD-L1 combination), Beigene/MapKure (led by Vihang Shah, focusing on selectivity and resistance), Vividion/Bayer, Novartis, GSK, and Deerfield Management (investing in early-stage PROTAC and novel scaffolds). The field is also actively pursuing resistance management—acquired mutations in the ATP-binding pocket or DNA-binding cleft (e.g., catalytic site variants) are expected as clinical use expands.

As the field matures, differentiation is shifting from simple target engagement to selectivity profiling against paralogous RecQ helicases (BLM, RECQL1, RECQL5), CNS penetration capabilities for glioma applications, and rational combination strategies with immune checkpoint inhibitors (anti-PD-1/PD-L1), ATR inhibitors, or PARP inhibitors. The next wave of R&D is targeting acquired resistance mutations and exploring PROTAC-mediated degradation as an alternative pharmacological strategy.

Competitive Modality & Indication Snapshot

Modality	Representative Players	Key Indications	Critical Assay Need (Why TarMart?)
Small Molecule Inhibitor	Ideaya Biosciences, Vihang Shah (Beigene/MapKure), Vividion/Bayer, Novartis, GSK, Deerfield Management	MSI-H CRC, Gastric Cancer, Endometrial Cancer	Helicase Activity Assay (Need high-purity WT vs Mutant proteins for mechanism validation and selectivity panel)
PROTAC Degrader	Emerging Academic/VC-backed	Solid Tumors (resistance prevention)	Protein-Protein Interaction (Need full-length WRN with native conformation for degradation assays)
Combination Therapy	Ideaya + Genentech (PD-L1); plus ATR/PARP combos	MSI-H Solid Tumors, Refractory MSI-H	Pathway Analysis (Need MLH1/PMS2 synthetic lethal validation tools, DDR pathway reagents)

Key Molecular Features & Mutations

WRN (UniProt Q14191) is a member of the RecQ helicase family, characterized by an N-terminal 3'-5' exonuclease domain, a central helicase ATP-binding domain, and a C-terminal helicase domain. Known variants include dbSNP:rs34477820, a somatic mutation found in colorectal cancer samples, and dbSNP:rs2230009 (no effect on exonuclease activity). These mutations provide context for assay development and resistance studies.

Assay Development Strategy & Recommended Workflow

Phase 1 – Biochemical Screening: Use FRET-based DNA unwinding and ATPase activity assays with high-purity WRN helicase domain (TarMart).

Phase 2 – Selectivity Profiling: Counter-screen against BLM, RECQL5, and RECQ1 using the TarMart RecQ Family Protein Panel.

Phase 3 – Cellular Validation: Test knockdown/knockout synthetic lethality in isogenic MSI-H vs MSS cell lines (e.g., HCT116 with/without MLH1) using WRN siRNA and lentivirus.

Phase 4 – Mechanism Confirmation: Use catalytic-dead mutants (E84A helicase-dead, D82A exonuclease-dead) for rescue experiments and target engagement assays.

Strategic Cross-Sell Targets

BLM (Bloom Syndrome Helicase): Required for selectivity profiling; TarMart provides BLM helicase domain protein.
MLH1: Biomarker for MSI-H and WRN sensitivity; TarMart offers wild-type and mutant MLH1 protein and antibodies.
RECQL5: Functional redundancy with WRN in certain tumor subtypes; potential resistance mechanism; TarMart supplies RECQL5 protein.
PARP1 & POLQ: DDR pathway targets frequently combined with WRN inhibitors for synergistic effects.